Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study.
R. Niesvizky
Consultant or Advisory Role - Celgene; Millennium; Onyx
Research Funding - Celgene; Millennium; Onyx
I. W. Flinn
Research Funding - Millennium
R. M. Rifkin
Consultant or Advisory Role - Celgene; Millennium
Honoraria - Amgen; Celgene; Cephalon; Millennium
N. Gabrail
No relevant relationships to disclose
V. Charu
Stock Ownership - Amgen; Bristol-Myers Squibb; Pfizer
Honoraria - Amgen; Novartis
Research Funding - Amgen; Celgene; GlaxoSmithKline; Roche
Y. Gaffar
No relevant relationships to disclose
R. Neuwirth
Employment or Leadership Position - Millennium
D. Corzo
Employment or Leadership Position - Millennium
J. Reeves
No relevant relationships to disclose